Advanced Glycation End Products Downregulate Connexin 43 and Connexin 40 in Diabetic Atrial Myocytes via the AMPK Pathway

References

• Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Svane J, Pedersen-Bjergaard U, Tfelt-Hansen J. Diabetes and the Risk of Sudden Cardiac Death. Curr Cardiol Rep. 2020;22(10):112. doi:10.1007/s11886-020-01366-2
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486
   PubMed Web of Science ®Google Scholar
• Yu M, Zhan X, Yang Z, Huang Y. Measuring the global, regional, and national burden of type 2 diabetes and the attributable risk factors in all 194 countries. J Diabetes. 2021;13(8):613–639. doi:10.1111/1753-0407.13159
   PubMed Web of Science ®Google Scholar
• Wang A, Green JB, Halperin JL, Piccini JP. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(8):1107–1115. doi:10.1016/j.jacc.2019.07.020
   PubMed Web of Science ®Google Scholar
• Twarda-Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced Glycation End-Products (AGEs): formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells. 2022;11(8):1312. doi:10.3390/cells11081312
   PubMed Web of Science ®Google Scholar
• Khalid M, Petroianu G, Adem A. Advanced Glycation End Products and Diabetes Mellitus: mechanisms and Perspectives. Biomolecules. 2022;12(4):542. doi:10.3390/biom12040542
   PubMed Web of Science ®Google Scholar
• Peppa M, Uribarri J, Vlassara H. Glucose, Advanced Glycation End Products, and Diabetes Complications: what Is New and What Works. Clin Diabetes. 2003;21(4):186–187. doi:10.2337/diaclin.21.4.186
   Google Scholar
• Fishman SL, Sonmez H, Basman C, et al. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018;24(1):59. doi:10.1186/s10020-018-0060-3
   PubMed Web of Science ®Google Scholar
• Bohm A, Urban L, Tothova L, et al. Advanced glycation end products predict long-term outcome of catheter ablation in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2022;64(1):17–25. doi:10.1007/s10840-021-00972-6
   PubMed Web of Science ®Google Scholar
• Chen YC, Lu YY, Wu WS, et al. Advanced glycation end products modulate electrophysiological remodeling of right ventricular outflow tract cardiomyocytes: a novel target for diabetes-related ventricular arrhythmogenesis. Physiol Rep. 2022;10(21):e15499. doi:10.14814/phy2.15499
   PubMed Web of Science ®Google Scholar
• Zheng DL, Wu QR, Zeng P, et al. Advanced glycation end products induce senescence of atrial myocytes and increase susceptibility of atrial fibrillation in diabetic mice. Aging Cell. 2022;21(12):e13734. doi:10.1111/acel.13734
   PubMed Web of Science ®Google Scholar
• Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354(25):2677–2688. doi:10.1056/NEJMoa052800
   PubMed Web of Science ®Google Scholar
• Dufeys C, Daskalopoulos EP, Castanares-Zapatero D, et al. AMPKα1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism. Basic Res Cardiol. 2021;116(1):10. doi:10.1007/s00395-021-00846-y
   PubMed Web of Science ®Google Scholar
• Su KN, Ma Y, Cacheux M, et al. Atrial AMP-activated protein kinase is critical for prevention of dysregulation of electrical excitability and atrial fibrillation. JCI Insight. 2022;7(8):e141213. doi:10.1172/jci.insight.141213
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Dang SP, Li SS, et al. Glucose Fluctuations Aggravate Myocardial Fibrosis via the Nuclear Factor-κB-Mediated Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation. Front Cardiovasc Med. 2022;9:748183. doi:10.3389/fcvm.2022.748183
   PubMed Web of Science ®Google Scholar
• Wu LD, Liu Y, Li F, et al. Glucose fluctuation promotes cardiomyocyte apoptosis by triggering endoplasmic reticulum (ER) stress signaling pathway in vivo and in vitro. Bioengineered. 2022;13(5):13739–13751. doi:10.1080/21655979.2022.2080413
   PubMed Web of Science ®Google Scholar
• Gong H, Chen H, Xiao P, et al. MiR-146a impedes the anti-aging effect of AMPK via NAMPT suppression and NAD+/SIRT inactivation. Signal Transduct Target Ther. 2022;7(1):66. doi:10.1038/s41392-022-00886-3
   PubMed Web of Science ®Google Scholar
• Yang Q, Shi Y, Jin T, et al. Advanced Glycation End Products Induced Mitochondrial Dysfunction of Chondrocytes through Repression of AMPKα-SIRT1-PGC-1α Pathway. Pharmacology. 2022;107(5–6):298–307. doi:10.1159/000521720
   PubMed Web of Science ®Google Scholar
• Qin W, Zhang L, Li Z, et al. Metoprolol protects against myocardial infarction by inhibiting miR-1 expression in rats. J Pharm Pharmacol. 2020;72(1):76–83. doi:10.1111/jphp.13192
   PubMed Web of Science ®Google Scholar
• Yamagishi SI, Sotokawauchi A, Matsui T. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation. Mini Rev Med Chem. 2019;19(13):1040–1048. doi:10.2174/1389557519666190311140737
   PubMed Web of Science ®Google Scholar
• Al-Saoudi E, Christensen MMB, Nawroth P, et al. Advanced glycation end-products are associated with diabetic neuropathy in young adults with type 1 diabetes. Front Endocrinol. 2022;13:891442. doi:10.3389/fendo.2022.891442
   PubMed Web of Science ®Google Scholar
• Méndez JD, Xie J, Aguilar-Hernández M, Méndez-Valenzuela V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem. 2010;341(1–2):33–41. doi:10.1007/s11010-010-0434-5
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Stehouwer CDA. Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age-Related Diseases. Physiol Rev. 2020;100(1):407–461. doi:10.1152/physrev.00001.2019
   PubMed Web of Science ®Google Scholar
• Maasen K, Eussen SJPM, Dagnelie PC, et al. Habitual intake of dietary methylglyoxal is associated with less low-grade inflammation: the Maastricht Study. Am J Clin Nutr. 2022;116(6):1715–1728. doi:10.1093/ajcn/nqac195
   PubMed Web of Science ®Google Scholar
• Thakur M, Tupe RS. Lipoxin and glycation in SREBP signaling: insight into diabetic cardiomyopathy and associated lipotoxicity. Prostaglandins Other Lipid Mediat. 2023;164:106698. doi:10.1016/j.prostaglandins.2022.106698
   PubMed Web of Science ®Google Scholar
• Patti G, Lucerna M, Cavallari I, et al. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. J Am Coll Cardiol. 2017;69(4):409–419. doi:10.1016/j.jacc.2016.10.069
   PubMed Web of Science ®Google Scholar
• Shah MS, Brownlee M. Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. Circ Res. 2016;118(11):1808–1829. doi:10.1161/CIRCRESAHA.116.306923
   PubMed Web of Science ®Google Scholar
• Noureldin M, Chen H, Bai D. Functional Characterization of Novel Atrial Fibrillation-Linked GJA5 (Cx40). Mutants Int J Mol Sci. 2018;19(4):977. doi:10.3390/ijms19040977
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu H, Zheng Q, et al. Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin. Life Sci. 2022;306:120826. doi:10.1016/j.lfs.2022.120826
   PubMed Web of Science ®Google Scholar
• Yan J, Thomson JK, Zhao W, et al. The stress kinase JNK regulates gap junction Cx43 gene expression and promotes atrial fibrillation in the aged heart. J Mol Cell Cardiol. 2018;114:105–115. doi:10.1016/j.yjmcc.2017.11.006
   PubMed Web of Science ®Google Scholar
• Ma JF, Yang F, Mahida SN, et al. TBX5 mutations contribute to early-onset atrial fibrillation in Chinese and Caucasians. Cardiovasc Res. 2016;109(3):442–450. doi:10.1093/cvr/cvw003
   PubMed Web of Science ®Google Scholar
• Tu T, Zhou S, Liu Z, Li X, Liu Q. Quantitative proteomics of changes in energy metabolism-related proteins in atrial tissue from valvular disease patients with permanent atrial fibrillation. Circ J. 2014;78(4):993–1001. doi:10.1253/circj.CJ-13-1365
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ni L, Zhang L, et al. Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy. Diabetes Metab Syndr Obes. 2021;14:227–240. doi:10.2147/DMSO.S289712
   PubMed Web of Science ®Google Scholar
• Višnjić D, Lalić H, Dembitz V, Tomić B, Smoljo T. AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: a Systematic Review. Cells. 2021;10(5):1095. doi:10.3390/cells10051095
   PubMed Web of Science ®Google Scholar